作者: Victor E Mulanovich , Shashank S Ghantoji , Roy F Chemaly , Dimpy P Shah , Ella J Ariza-Heredia
DOI:
关键词:
摘要: Advances in stem cell transplantation procedures and the overall improvement clinical management of hematopoietic transplant (HCT) recipients over past 2 decades have led to an increase survival duration, part owing better strategies for prevention treatment post-transplant complications, including opportunistic infections. However, post-HCT infections remain a concern HCT recipients, particularly caused by community respiratory viruses (CRVs), which can lead significant morbidity mortality. These potentially cause lower tract illness, is associated with higher mortality rate among recipients. Clinical CRV includes supportive care antiviral therapy, especially high-risk individuals, when available. Directed therapy only available influenza infections, where successful use neuraminidase inhibitors (oseltamivir or zanamivir) and/or M2 (amantadine rimantadine) has been reported. Data on ribavirin, without immunomodulators, syncytial virus emerged but still controversial at best because lack randomized controlled trials. Because directed most these viruses, should be emphasized healthcare workers, patients, family, friends include promotion licensed inactivated vaccine indicated. In this review, we discuss special patient population, focusing commercially antivirals, adjuvant novel drugs under investigation, as well means prevention.